Can oral terbinafine be used in a patient with tinea corporis who has mildly elevated transaminases?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 6, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Oral Terbinafine Should NOT Be Used in Patients with Mildly Elevated Transaminases for Tinea Corporis

Systemic terbinafine is not recommended in patients with active or chronic liver disease, and baseline liver function tests are required before initiating treatment 1. The FDA drug label and British Association of Dermatologists guidelines explicitly state this contraindication, prioritizing patient safety over treatment of a non-life-threatening condition like tinea corporis.

Key Evidence Against Use

Contraindications from Guidelines and Drug Labels

The most authoritative sources are clear:

  • Griseofulvin guidelines list "severe liver disease" as a contraindication 2, and while terbinafine's contraindications aren't explicitly stated in the tinea capitis guidelines, the onychomycosis guidelines are definitive
  • The British Association of Dermatologists' onychomycosis guidelines (2014) explicitly state: "systemic terbinafine is not recommended in patients with active or chronic liver disease" 1
  • Baseline liver function tests and complete blood count are recommended before starting terbinafine, particularly in patients with history of heavy alcohol consumption, hepatitis, or haematological abnormalities 1
  • The FDA drug label mandates measurement of serum transaminases (ALT and AST) before taking terbinafine 3

Hepatotoxicity Risk Profile

While rare, the hepatotoxicity risk is real and potentially severe:

  • Rare reports of serious hepatic toxicity have occurred, usually in patients with pre-existing liver disease 1
  • Terbinafine has been associated with liver problems that can lead to the need for liver transplant or death 3
  • Patients must be advised to immediately report symptoms of liver injury (persistent nausea, anorexia, fatigue, vomiting, right upper abdominal pain, jaundice, dark urine, pale stools), and treatment should be discontinued 3

Alternative Approach for Tinea Corporis

For tinea corporis specifically, you have safer options:

Topical Therapy First-Line

  • Topical terbinafine 1% formulations achieve mycological cure in >80% of patients with tinea corporis when applied once or twice daily for up to 2 weeks 4
  • This avoids systemic exposure entirely in a patient with hepatic concerns

If Systemic Therapy Required

If the infection is extensive and truly requires systemic treatment:

  1. Consider griseofulvin instead - while it lists "severe liver disease" as a contraindication 2, the threshold appears higher than for terbinafine, and it has 50+ years of safety experience
  2. Itraconazole may be an alternative, though it also requires hepatic monitoring
  3. Address the underlying cause of transaminase elevation first - if reversible, treat the tinea corporis topically while optimizing liver function, then reassess need for systemic therapy

Critical Clinical Pitfall

The major pitfall here is underestimating the significance of "mildly elevated" transaminases. The guidelines don't distinguish between mild, moderate, or severe elevation - they state pre-existing liver disease is a relative or absolute contraindication. Even mild elevations suggest hepatic dysfunction that could be exacerbated by terbinafine, with potentially catastrophic consequences for what is ultimately a superficial, non-life-threatening infection.

Practical Algorithm

  1. Document baseline transaminase values - determine if truly "mild" (1-2x ULN) or higher
  2. Investigate cause of elevation - alcohol, viral hepatitis, fatty liver, medications
  3. Start topical terbinafine 1% cream twice daily for 2 weeks for tinea corporis 4
  4. If topical therapy fails and systemic treatment is absolutely necessary:
    • Optimize liver function if possible
    • Consider griseofulvin as safer alternative
    • If terbinafine must be used, obtain informed consent about hepatotoxicity risk
    • Monitor LFTs weekly for first month, then every 2 weeks
    • Discontinue immediately if transaminases worsen

The risk-benefit ratio does not favor oral terbinafine in this scenario when safer alternatives exist for a condition that poses no mortality risk.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.